CureVac, a German biopharmaceutical company, has hit the headlines after US President Trump tried to secure exclusive rights to its developmental coronavirus vaccine. The vaccine is being developed to prevent the spread of coronavirus (SARS-CoV-2), which causes COVID-19. Trump is reported to have offered large sums of money to those working on the vaccine, in a move designed to give the US complete control over it. Trump’s actions are reported to have angered German politicians and have prompted Berlin to offer financial incentives to the company.
For children with suspected community-acquired pneumonia (CAP) who are discharged from the emergency department, outcomes do not differ between those who do and those who do not receive antibiotic prescriptions, according to a study published online March 16 in Pediatrics.